Why Editas Medicine Is Now the CRISPR Stock to Really Watch

Based on market cap, CRISPR Therapeutics (NASDAQ: CRSP) ranks as the top biotech focused on developing CRISPR gene-editing therapies. It's more than 2 1/2 times the size of Editas Medicine (NASDAQ: EDIT) and nearly four times larger than Intellia Therapeutics (NASDAQ: NTLA).

But based on stock performance so far in 2020, Intellia wins the prize as the hottest CRISPR biotech stock. Its shares have soared more than 40%, thanks in large part to the expansion of its partnership with Regeneron.

While CRISPR Therapeutics and Intellia have captured investors' attention lately, Editas Medicine could now be the CRISPR stock to really watch. There are both near-term and long-term reasons why investors should keep their eyes on this company.

Continue reading

Source Fool.com